<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01440231</url>
  </required_header>
  <id_info>
    <org_study_id>EMR 700461-018</org_study_id>
    <secondary_id>BB-IND 11,584</secondary_id>
    <nct_id>NCT01440231</nct_id>
  </id_info>
  <brief_title>Atacicept Demonstrating Dose RESponSe</brief_title>
  <acronym>ADDRESS</acronym>
  <official_title>A Phase II, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Multidose, 24-Week Dose-Response Study to Evaluate the Efficacy and Safety of Atacicept in Subjects With Systemic Lupus Erythematosus (SLE)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>EMD Serono</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>EMD Serono</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Systemic lupus erythematosis (SLE) is an autoimmune disease, meaning that the body's immune&#xD;
      system attacks its own organs and tissues. Within the immune system, B-cells and plasma cells&#xD;
      make proteins called antibodies, which in autoimmune disease can bind to one's own tissues&#xD;
      and are thus referred to as autoantibodies. Atacicept blocks 2 factors in the body, called&#xD;
      BLyS and APRIL, which are important for the maintenance of B-cells and plasma cells, and thus&#xD;
      the production of antibodies. This study will assess whether treatment with atacicept can&#xD;
      reduce SLE disease activity. Atacicept is still an experimental drug, meaning that it is not&#xD;
      available outside of a clinical trial, and that its potential benefits and risks have not&#xD;
      been fully determined.&#xD;
&#xD;
      A total of 175 subjects are planned to be randomized (35 subjects per treatment arm) in a&#xD;
      1:1:1:1:1 ratio to receive either atacicept 5 mg, atacicept 25 mg, atacicept 75 mg, atacicept&#xD;
      115 mg or matching placebo, given subcutaneously once weekly for 24 weeks.&#xD;
&#xD;
      The primary objective of the trial is to evaluate the efficacy of atacicept compared to&#xD;
      placebo in reducing SLE disease activity in subjects treated with standard of care (SoC)&#xD;
      therapy and to investigate the dose-response relationship.&#xD;
&#xD;
      The secondary objectives of the trial are:&#xD;
&#xD;
        -  To evaluate the effect of atacicept in reducing corticosteroid usage&#xD;
&#xD;
        -  To evaluate the safety and tolerability profile of atacicept in subjects with SLE&#xD;
&#xD;
        -  To confirm the PK and PD profiles of atacicept in SLE subjects&#xD;
&#xD;
        -  To evaluate the changes in the Medical Outcomes Study Short Form General Health Survey&#xD;
           [SF-36].&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <start_date>February 2012</start_date>
  <completion_date type="Anticipated">February 2014</completion_date>
  <primary_completion_date type="Anticipated">August 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline (trial day 1) in SLEDAI-2K Responder Index-50 (SRI-50) at week 24 of therapy</measure>
    <time_frame>24 weeks</time_frame>
    <description>The SRI-50 is a modification of the SLEDAI-2K, and allows detection of partial improvements (at least 50%) in SLE signs and symptoms assessed by SLEDAI-2K (Systemic Lupus Erythamtosus Disease Activity Index- 2000).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline to Week 24 in corticosteroid dose</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in serum Complement C3 levels at week 24 in subjects with low C3 at baseline</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in serum Complement C4 levels at week 24 in subjects with low C4 at baseline</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in anti-dsDNA antibodies (in subjects with anti dsDNA ≥30 IU/mL at baseline) and in ANA levels (in subjects with HEp-2 ANA ≥1:80 at baseline) at week 24</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in levels of total Ig and Ig classes (IgG, IgA, and IgM) at week 24</measure>
    <time_frame>24 weekls</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The nature (preferred terms) and incidence of AEs</measure>
    <time_frame>24 weeks</time_frame>
    <description>Frequency tables summarizing the observed number of AEs by System Organ Class (SOC) and preferred term will be presented per regimen</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Systemic Lupus Erythematosus</condition>
  <arm_group>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching placebo administered by subcutaneous injection, once weekly</description>
    <arm_group_label>Arm 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atacicept</intervention_name>
    <description>Atacicept 5 mg administered by subcutaneous injection, once weekly</description>
    <arm_group_label>Arm 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atacicept</intervention_name>
    <description>Atacicept 25 mg administered by subcutaneous injection, once weekly</description>
    <arm_group_label>Arm 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atacicept</intervention_name>
    <description>Atacicept 75 mg administered by subcutaneous injection, once weekly</description>
    <arm_group_label>Arm 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atacicept</intervention_name>
    <description>Atacicept 115 mg administered by subcutaneous injection, once weekly</description>
    <arm_group_label>Arm 5</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female of ≥18 years of age&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
          -  Diagnosis of SLE satisfying at least 4 out of the 11 ACR criteria during the course of&#xD;
             their illness&#xD;
&#xD;
          -  Disease duration of at least 6 months&#xD;
&#xD;
          -  SLEDAI-2K score ≥ 6 at screening&#xD;
&#xD;
          -  Positive test results for antinuclear antibody (ANA) (HEp-2 ANA ≥1:80) and/or&#xD;
             anti-double-stranded deoxyribonucleic acid (dsDNA) (≥30 IU/mL) at screening&#xD;
&#xD;
          -  Negative serum pregnancy test and highly effective method of contraception for woman&#xD;
             of childbearing potential.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Increase in dosing of corticosteroids within 2 weeks prior to screening&#xD;
&#xD;
          -  Introduction of MMF within 3 months prior to TD1 or increase in dosing within 1 month&#xD;
             before screening&#xD;
&#xD;
          -  Change in dosing of immunosuppressants or corticosteroids during the screening period&#xD;
&#xD;
          -  Serum IgG &lt; 6g/L&#xD;
&#xD;
          -  Estimated Glomerular Filtration Rate (GFR) &lt;50 mL/min/1.73m²&#xD;
&#xD;
          -  Urinary protein:creatinine ratio &gt;2 mg/mg&#xD;
&#xD;
          -  History of demyelinating disease&#xD;
&#xD;
          -  Breastfeeding or pregnancy&#xD;
&#xD;
          -  Legal or limited legal capacity&#xD;
&#xD;
        Additional exclusion criteria also apply&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stephen Wax, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>EMD Serono, Senior Medical Director, Rheumatology</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>August 2013</verification_date>
  <study_first_submitted>September 22, 2011</study_first_submitted>
  <study_first_submitted_qc>September 23, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 26, 2011</study_first_posted>
  <last_update_submitted>August 20, 2013</last_update_submitted>
  <last_update_submitted_qc>August 20, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 21, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Rheumatology</keyword>
  <keyword>Double-Blind</keyword>
  <keyword>Placebo-Controlled</keyword>
  <keyword>Multidose</keyword>
  <keyword>Dose-Response</keyword>
  <keyword>Phase II</keyword>
  <keyword>Systemic Lupus Erythematosus</keyword>
  <keyword>SLE</keyword>
  <keyword>Atacicept</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lupus Erythematosus, Systemic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

